Antimalarial agents: Closing the gate on toll‐like receptors?
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Antimalarial agents have a long history of efficacy in systemic lupus erythematosus (SLE). Initially understood to treat skin disease, they are known to also relieve arthritis and pleurisy. In addition to these therapeutic benefits, they likely have a role in prophylaxis of disease activation. Should all SLE patients be taking antimalarials? The answer to this requires more information regarding its prophylactic efficacy and is complicated by continuing concerns about retinal toxicity. The clinical use of antimalarial drugs might be significantly aided by better understanding of how they work. We will discuss here advances in several areas that provide a basis for understanding how antimalarials work in SLE and how they might be better utilized in the future. Over the last several years, a paradigm shift in understanding the importance of the innate immune system in SLE has been driven by the recognition that a class of pattern recognition receptors (PRRs), collectively known as Toll-like receptors (TLRs), likely contributes to pathogenesis. TLRs are best known for their ability to discriminate microbial macromolecules from host tissue and thereby rapidly activate the innate immune system. However, it has become increasingly apparent in recent years that select host molecules, especially nucleic acids, can serve as endogenous TLR ligands (for review, see refs. 1 and 2), perhaps promoting responses to damaged tissue (3). Notably, these receptors are harbored in intracellular compartments and therefore not normally accessible to circulating nucleic acids. However, receptors expressed by B cells (surface IgM), dendritic cells (DCs) (Fc receptor [FcR]), or other antigen-presenting cells can act as key intermedi
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of lung injury and repair by Toll-like receptors and hyaluronan
Jiang, D., Liang, J., Fan, J., Yu, S., Chen, S., Luo, Y., Prestwich, G. D., Mascarenhas, M. M., Garg, H. G., Quinn, D. A., et al. (2005) · Nature Medicine · doi:10.1038/nm1315 · Cited by 1,401
Cited by
Systemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., & Sève, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102567 · Cited by 658
Rainsford, K. D., Parke, A. L., Clifford-Rashotte, M., & Kean, W. F. (2015) · Inflammopharmacology · doi:10.1007/s10787-015-0239-y · Cited by 543
Izmirly, P. M., Costedoat-Chalumeau, N., Pisoni, C. N., Khamashta, M. A., Kim, M. Y., Saxena, A., Friedman, D., Llanos, C., Piette, J.-C., & Buyon, J. P. (2012) · Circulation · doi:10.1161/circulationaha.111.089268 · Cited by 456
Toll‐like receptors 7, 8, and 9: linking innate immunity to autoimmunity
Krieg, A. M., & Vollmer, J. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00572.x · Cited by 350
Metadata
- Authors
- Lafyatis, R., York, M., & Marshak‐Rothstein, A.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2006-09-28
- Volume
- 54
- Issue
- 10
- Pages
- 3068-3070
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2015744687
- Cited by
- 150
- References
- 1
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antimalarial agents: Closing the gate on toll‐like receptors? https://app.cochat.ai/papers/10.1002/art.22157
- The paper
- Lafyatis, R., York, M., & Marshak‐Rothstein, A. (2006). Antimalarial agents: Closing the gate on toll‐like receptors? Arthritis & Rheumatism. https://doi.org/10.1002/art.22157
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.